Early Stage Pharmaceutical Development, Genentech Inc., 1 DNA Way, South San Francisco, California, 94080, USA.
Seattle Genetics, Bothell, Washington, USA.
Pharm Res. 2018 Oct 2;35(11):222. doi: 10.1007/s11095-018-2467-5.
Biotherapeutics can be susceptible to oxidation during manufacturing and storage. Free L-methionine is known to protect methionine residues in proteins from oxidation. Similarly, free tryptophan and other indole derivatives have been shown to protect tryptophan residues from oxidation. N-acetyl-DL-tryptophan was previously identified as a potentially superior antioxidant to tryptophan as it has a lower oxidation potential and produces less peroxide upon light exposure. This study sought to confirm the antioxidant efficacy and safety of N-acetyl-DL-tryptophan and L-methionine as formulation components for biotherapeutic drugs.
Antibodies were subjected to AAPH and light exposure in the presence of N-acetyl-DL-tryptophan and L-methionine. Oxidation in relevant CDR and Fc residues was quantified by peptide map. In silico, in vitro, and in vivo studies were performed to evaluate the safety of N-acetyl-DL-tryptophan and L-methionine.
Peptide mapping demonstrated that N-acetyl-DL-tryptophan was effective at protecting tryptophans from AAPH stress, and that the combination of N-acetyl-DL-tryptophan and L-methionine protected both tryptophan and methionine from AAPH stress. The safety assessment suggested an acceptable safety profile for both excipients.
N-acetyl-tryptophan and L-methionine effectively reduce the oxidation of susceptible tryptophan and methionine residues in antibodies and are safe for use in parenteral biotherapeutic formulations.
生物治疗药物在生产和储存过程中可能容易氧化。游离 L-蛋氨酸已知可保护蛋白质中的蛋氨酸残基免受氧化。同样,游离色氨酸和其他吲哚衍生物已被证明可保护色氨酸残基免受氧化。N-乙酰-DL-色氨酸以前被确定为一种潜在的优于色氨酸的抗氧化剂,因为它的氧化电位较低,并且在光照下产生的过氧化物较少。本研究旨在确认 N-乙酰-DL-色氨酸和 L-蛋氨酸作为生物治疗药物制剂成分的抗氧化功效和安全性。
在存在 N-乙酰-DL-色氨酸和 L-蛋氨酸的情况下,使抗体经受 AAPH 和光照。通过肽图定量测定相关 CDR 和 Fc 残基中的氧化。进行了体内、体外和体内研究,以评估 N-乙酰-DL-色氨酸和 L-蛋氨酸的安全性。
肽图表明,N-乙酰-DL-色氨酸可有效保护色氨酸免受 AAPH 应激,并且 N-乙酰-DL-色氨酸和 L-蛋氨酸的组合可保护色氨酸和蛋氨酸免受 AAPH 应激。安全性评估表明两种赋形剂均具有可接受的安全性特征。
N-乙酰色氨酸和 L-蛋氨酸可有效减少抗体中易受氧化的色氨酸和蛋氨酸残基的氧化,并且可安全用于肠胃外生物治疗制剂。